The eve of bid opening!

This is a competition of strength! The price reduction strategy requires the company to have a strong ability to control costs, which is easier said than done; the price protection strategy requires the company to have a strong brand building ability, which poses a huge challenge to the marketing te.

On June 20, Shanghai Sunshine Pharmaceutical Purchasing Network released the seventh batch of centralized procurement documents "National Drug Centralized Procurement Document (GY-YD2022-1)", which is also the major document "General Office of the State Council on promoting The third centralized procurement after the release of the Opinions on the Normalization and Institutionalization of the Centralized and Volume-Based Procurement of Dru.

A total of 61 varieties were collected this time, involving cardiovascular, infection, tumor, diabetes, nervous system and other disease fields, affecting the products of hundreds of pharmaceutical compani.

It can be seen that this collection is of great significance to the organizers and contestants, and must not be taken light.

stabilization policy

The document of the General Office of the State Council on the normalization of centralized procurement is equivalent to the basic law of centralized drug procurement in Chi.

For example, shortlisted companies determine the criter.

stable supply

According to incomplete statistics, since the launch of centralized drug procurement, nearly 20 companies have experienced supply cuts, and drug quality and production line adjustments have become common reaso.

For details, see clause 13 of the centralized acquisition docume.

Steady price reduction

Adhere to the integration of recruitment and procurement, and link volume and pri.

A shortlisted enterprise that meets both of the first and second conditions will be eligible to be select.

Scenario 1: The price meets one of the following terms

11 "Comparable price per unit" ≤ 8 times the lowest "comparable price per unit" of the same varie.

12 "Comparable unit price" ≤ 1000 yu.

13 The decrease of "unit declared price" is ≥500% (the decrease is calculated based on the highest valid declared price of the corresponding specification in the "Catalogue of Purchased Varieties", calculated as a percentage, and the percentage is rounded to 2 decimal place.

Scenario 2: Shortlisted companies that meet Scenario 1 meet one of the following terms

14 After meeting the first condition, it is not the highest ranking among the same varieti.

15 After meeting the first condition, the same variety is the highest ranking, and the ratio is calculated according to "the highest ranking 'unit comparable price' of the same variety / the lowest ranking 'unit comparable price' of the same variety", and the ratio results of all varieties in this centralized collection Non-top 6 in descending ord.

Stable strategy

As far as competing pharmaceutical companies are concerned, the strategy should be clear and stable after many trials of centralized procureme.

In a nutshell, it is nothing more than two different directions of "price reduction and selection" and "price protectio.

For example, for omeprazole injection, the agreed purchasing base for the first year (total of all specifications) is 861 million pieces, and 28 qualified companies participate in the competiti.

With such fierce competition, such a large market capacity, and it is an injection dosage form, it is obviously the best policy to reduce the price and seek the best choi.

On the contrary, for the oral normal-release dosage form of flunarizine, although the agreed purchase volume calculation base in the first year is as high as 580 million tablets, the highest effective declared price is only 2 yu.

If a brand has strong market influence, choose to insure the price and occupy the centralized procureme.

It may also be a wise move to go outside the (own expense) mark.

No matter which strategy you choose, the strength requirements for the enterprise are very hi.

The price reduction strategy requires companies to have strong cost control capabilities, which is easier said than done; the price protection strategy requires companies to have strong brand building capabilities, which poses a huge challenge to the marketing te.

Therefore, it is necessary to implement policies according to the product, one product for one policy, especially the calculation of the bidding price, which needs to be carefully considered and should not be carele.

chance point?

According to Note 7 and Note 8 of the catalogue of products for centralized procurement, “In the same variety, if the large-volume injection and the small-volume injection compete in the same group, the difference between the large-volume injection and the small-volume injection is calculated at 5 yuan, and the variety of iodine involved is For patrol injection, milrinone injection, edaravone injection and zoledronic acid injection (variety .

44), the highest effective declaration price does not include the differen.

In the same variety, the ready-to-match powder-liquid dual-chamber bag preparation is the same as Small-volume injections compete in the same group, the difference between ready-to-mix powder-liquid dual-chamber bag formulations and small-volume injections is calculated at 15 yuan, involving varieties of cefmetazole injection and cefepime injection, and the highest effective declaration price does not include the differen.

”

This provision is in line with the relevant provisions of the fifth centralized procureme.

The author believes that relevant enterprises should fully investigate and make good use of this ru.

If the difference (markup) is sufficient to cover its cost, it is extremely beneficial for large volume injections and ready-to-mix powder-liquid dual-chamber bag formulatio.

Conclusion<<<

The centralized procurement of medicines affects the whole bo.

On the basis of retaining previous experience, this centralized procurement is the first to create a new model for the main supply area and the backup supply area, which is conducive to further ensuring the stability of drug supp.

The price difference between the ready-to-mix powder-liquid dual-chamber bag preparation and the small-volume injection remains 15 yuan, which may be beneficial to the application and promotion of innovative packaging preparations, protect the innovative spirit of entrepreneurs, and promote the upgrading of pharmaceutical produc.

In short, this centralized procurement is mainly based on stability, and policy patches will be given in time to the problems of supply interruptions that have been exposed in the past, so as to be more perfe.

It is believed that this centralized procurement will achieve the expected effect, while greatly reducing the price of drugs, while effectively ensuring the supply and reducing the burden of patients on medicati.